Lemonade stock jumps 5.6% in premarket ahead of earnings — what LMND traders are watching

Lemonade stock jumps 5.6% in premarket ahead of earnings — what LMND traders are watching

February 19, 2026

New York, Feb 19, 2026, 05:17 (ET) — Premarket

  • Lemonade shares gained 5.6% ahead of the bell, with the insurer set to release its results later this Thursday.
  • The stock finished Wednesday at $65.73, then was changing hands at $69.39 in premarket action.
  • Loss ratios, premium growth, and updates to the company’s profitability timeline are getting extra attention.

Lemonade Inc shares jumped 5.6% to $69.39 in premarket action Thursday, building on Wednesday’s rally as traders braced for the online insurer’s quarterly numbers.

Lemonade’s update comes as investors show little patience for unprofitable growth stocks—any whiff of looser underwriting or ballooning costs has drawn sharp reactions lately. The shares are known for big swings around earnings. This report will set the tone heading into the next few months.

Wall Street’s expecting Lemonade to post a smaller loss this time, driven by quicker sales. Analysts polled by Investing.com peg the loss at 39 cents per share on $216.3 million in revenue. Investors are zeroed in on whether Lemonade can keep shaving down its loss ratio—the percentage of premiums paid out in claims. Truist Securities’ Arvind Ramnani has pitched Lemonade’s approach as one with “significant structural advantages such as a lower overall cost base relative to traditional insurers.” Investing

Lemonade, in its latest shareholder letter, projected fourth-quarter revenue between $217 million and $222 million, with an adjusted EBITDA loss forecast at $13 million to $16 million. For in-force premium, the company sees $1.218 billion to $1.223 billion—this figure reflects annualized premium active at period end. Lemonade kept its outlook for positive adjusted EBITDA in the fourth quarter of 2026 unchanged.

Autos are still the wild card. Lemonade has moved further into car insurance, rolling out a product in January that’s connected to Tesla’s Full Self-Driving driver assistance software. Reuters says drivers get a 50% discount on miles logged with FSD turned on. Co-founder Shai Wininger told Reuters the deal relies on “extremely high resolution” telemetry that can separate assisted miles from those driven by humans. Reuters

Filings often draw investor attention during earnings season. On Feb. 12, Chief Insurance Officer John Sheldon Peters exercised stock options, picking up 11,845 shares at $11.61 each, according to a Form 4 filing.

Lemonade finds itself squeezed in a packed field. It’s not just up against fellow insurtechs; established insurers push back hard in auto and homeowners. Pricing whipsaws, claims severity jumps—this is familiar ground for industry veterans, and Lemonade’s right in the mix.

Investors are keeping tabs on the usual suspects: loss ratios, marketing costs, premium growth speed. One key question—how’s the company managing car growth, which tends to be a tougher underwriting play, while still pushing for better margins in other lines?

Still, the risks are clear enough. Severe weather can drive up property claims, while auto claims stay vulnerable to higher repair costs and changes in claim frequency. Should loss ratios worsen or management take a more guarded stance, that early premarket pop in the stock might not last long.

Lemonade plans to publish its fourth-quarter 2025 earnings before the U.S. market opens Thursday, with the earnings call slated for 8:00 a.m. ET.

Stock Market Today

  • Optiscan Imaging Partners with Mayo Clinic to Enhance Robotic Surgery
    June 2, 2026, 9:45 PM EDT. Optiscan Imaging (ASX:OIL) CEO Dr Camile Farah detailed progress in integrating the company's advanced imaging technology into robotic surgical platforms through collaboration with Mayo Clinic. The partnership targets the expanding robotic surgery market, valued for minimally invasive operations using automated systems. Dr Farah outlined the next phases involving preclinical and clinical studies to validate the technology's effectiveness. This development marks a significant commercial opportunity amid growing adoption of robotic surgery solutions worldwide.